Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Prurigo nodularis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Trevi Therapeutics
  • Most Recent Events

    • 12 Jan 2023 Results of population pharmacokinetic-pharmacodynamic model assessing efficacy of nalbuphine ER in patients with prurigo nodularis from two clinical trials (NCT02373215: 9 healthy subjects; NCT02174419: 62 subjects with PN), published in the British Journal of Clinical Pharmacology.
    • 28 Mar 2022 Results of supplementary analyses assessing the psychometric properties of the Worst Itch Numeric Rating Scale, published in the Journal of the European Academy of Dermatology and Venereology
    • 01 Mar 2022 Results published in the Journal of the European Academy of Dermatology and Venereology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top